Retatrutide Dosing in Clinical Trials
Retatrutide is administered as a once-weekly subcutaneous injection, similar to other incretin-based therapies like semaglutide and tirzepatide. The dosing protocols used in clinical trials provide important insights into how the drug will likely be prescribed if approved.
Important disclaimer: Retatrutide is an investigational drug that has not been approved by the FDA or any regulatory agency. The dosing information below is based on clinical trial protocols and is provided for educational purposes only. Do not attempt to self-administer retatrutide.
Dose Ranges Studied
Clinical trials have evaluated retatrutide across a wide dose range:
Phase 1b Trial Doses [1]
- 0.5 mg once weekly
- 1.5 mg once weekly
- 3.0 mg once weekly
- 4.5 mg once weekly
- 6.0 mg once weekly
- 8.0 mg once weekly
- 12.0 mg once weekly
Phase 2 Obesity Trial Doses [2]
- 1 mg (maintenance dose)
- 4 mg (maintenance dose)
- 8 mg (maintenance dose)
- 12 mg (maintenance dose)
Phase 2 Diabetes Trial Doses [3]
- 0.5 mg (maintenance dose)
- 4 mg (two different escalation regimens)
- 8 mg (maintenance dose)
- 12 mg (maintenance dose)
Dose Escalation Protocol
A critical aspect of retatrutide dosing is the gradual dose escalation approach. Rather than starting at the target maintenance dose, patients begin at a low dose and increase incrementally over several weeks. This approach significantly reduces the incidence and severity of gastrointestinal side effects.
Typical Escalation Schedule (Phase 2 Obesity Trial)
For the 12 mg target dose, the escalation followed approximately this pattern:
- Weeks 1-4: Starting dose (e.g., 2 mg)
- Weeks 5-8: Intermediate dose (e.g., 4 mg)
- Weeks 9-12: Higher intermediate dose (e.g., 8 mg)
- Weeks 13+: Target maintenance dose (12 mg)
The exact escalation schedule varied between trials and dose groups, but the principle of gradual titration was consistent across all studies.
Why Dose Escalation Matters
Starting at a low dose and gradually increasing allows the body to adapt to the drug's effects, particularly:
- GI tolerance: The nausea, vomiting, and diarrhea associated with GLP-1 agonism are most pronounced when treatment begins or doses increase; gradual titration minimizes these effects
- Metabolic adjustment: The body needs time to adapt to changes in appetite, gastric emptying, and energy metabolism
- Safety monitoring: Gradual escalation allows clinicians to monitor for adverse effects at each dose level before increasing
Dose-Response Relationships
Weight Loss
The relationship between retatrutide dose and weight loss is clearly dose-dependent:
- 1 mg: ~8.7% weight loss
- 4 mg: ~17.1% weight loss
- 8 mg: ~22.8% weight loss
- 12 mg: ~24.2% weight loss
The incremental benefit diminishes at higher doses (the jump from 8 mg to 12 mg is smaller than from 4 mg to 8 mg), suggesting a flattening dose-response curve.
A1C Reduction
Interestingly, the glycemic dose-response is not strictly linear:
- 8 mg: ~1.99% A1C reduction
- 12 mg: ~1.91% A1C reduction
The slightly lower A1C reduction at 12 mg compared to 8 mg may reflect increased glucagon receptor activation at the highest dose, which partially offsets glucose-lowering effects.
Side Effects
Adverse events are clearly dose-dependent, with higher doses associated with more GI side effects and higher discontinuation rates. The 12 mg dose had a 16% discontinuation rate compared to 6% at 8 mg.
Optimal Dose Selection
The optimal dose will likely depend on the treatment goal and individual patient tolerance:
- For maximum weight loss: 12 mg appears optimal, though 8 mg provides nearly as much weight loss with better tolerability
- For type 2 diabetes: 8 mg may offer the best balance of glycemic control and tolerability
- For liver fat reduction: Higher doses (8-12 mg) showed the most dramatic liver fat reductions
- For patients with GI sensitivity: Lower doses (4 mg) still provide clinically meaningful benefits with fewer side effects
Administration
Injection Technique
- Route: Subcutaneous (under the skin)
- Frequency: Once weekly, on the same day each week
- Injection sites: Abdomen, thigh, or upper arm (rotating sites)
- Timing: Can be administered at any time of day, with or without meals
Pharmacokinetics
The Phase 1b trial established that retatrutide has pharmacokinetics suitable for once-weekly dosing, with a half-life that maintains therapeutic drug levels throughout the dosing interval [1].
What to Expect If Approved
If retatrutide receives FDA approval, the prescribing information will likely include:
- A recommended starting dose with a defined escalation schedule
- Multiple maintenance dose options to allow individualized treatment
- Guidance on dose adjustment based on tolerability
- Specific instructions for missed doses
References
-
Urva S, et al. "LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b trial." The Lancet. 2022;400(10366):1869-1881. PubMed: 36354040
-
Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." NEJM. 2023;389(6):514-526. PubMed: 37366315
-
Rosenstock J, et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes." The Lancet. 2023;402(10401):529-544. PubMed: 37385280
